Xilio Therapeutics, Inc.
XLO
$7.73
$0.000.00%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/12/2026
-
Seeking Alpha - Healthcare
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Zacks Investment Research
5/12/2026
-
Globe Newswire
5/11/2026
-
Zacks Investment Research
5/11/2026
-
Zacks Investment Research
5/7/2026
-
Globe Newswire
5/4/2026
-
The Cerbat Gem
4/17/2026
-
TipRanks Financial Blog
4/17/2026
-
Globe Newswire
4/16/2026
-
TipRanks Financial Blog
4/16/2026
-
Globe Newswire
4/3/2026
-
Globe Newswire
4/1/2026
-
Zacks Investment Research
4/1/2026
-
Zacks Investment Research
4/1/2026
-
Zacks Investment Research
3/28/2026
-
MarketBeat
3/26/2026
-
Zacks Investment Research
3/23/2026
-
Globe Newswire
3/17/2026
-
Globe Newswire
3/17/2026
-
MarketBeat
3/16/2026
-
Ticker Report
3/16/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Monday, March 23, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
857 524 2466
Address
828 Winter Street
Waltham, MA 02451
Waltham, MA 02451
Country
Year Founded
Business Description
Sector
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a...
more